The European Medicines Agency has granted orphan drug designation to AB8939, developed by AB Science, for treating acute myeloid leukemia, following a similar designation from the US FDA.
AB Science is re-examining the marketing authorization application for masitinib in amyotrophic lateral sclerosis (ALS) with the EMA and Health Canada.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.